Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, is used in treatment of autoimmune diseases. Commonly known side effects of golimumab are injection site reaction, headache, and gastrointestinal discomfort. Although a few cases of pompholyx and eczematous eruption after immunoglobulin therapy were reported, there is no reported pompholyx and eczematous eruption after golimumab injection. A 38-year-old man who was treated with biologics for ulcerative colitis presented with scattered eczematous patches and pustules on whole body, especially on his hands. After he had been diagnosed as ulcerative colitis, he was treated with many drugs such as systemic steroid, infliximab and adalimumab. Because these therapy was ineffective, treatment strategy was changed into the subcutaneous injection of golimumab 100mg according to conventional dosing schedule. Although this therapy helped to relieve his symptom of ulcerative colitis, scattered, eczematous, indurated patches and pustules appeared on his whole body after the second injection. The histologic specimen from hand showed acanthosis, spongiosis and intraepidermal vesicles, and perivascular cell infiltrate in the upper dermis, which was consistent with pompholyx. Herein, we reported a rare case of pompholyx and eczematous eruption associated with golimumab therapy.